Literature DB >> 19431188

Modeling ATM mutant proteins from missense changes confirms retained kinase activity.

Giancarlo Barone1, Alix Groom, Anne Reiman, Venkataramanan Srinivasan, Philip J Byrd, A Malcolm R Taylor.   

Abstract

Ataxia-telangiectasia mutated (ATM) is the gene mutated in the cancer-predisposing disorder ataxia-telangiectasia (A-T). We modeled ATM sequence variants identified in UK A-T patients to determine the stability and kinase activity of the resulting proteins as well as the distribution of these mutations across the coding region. Of 20 missense changes modeled, 10 proteins showed ATM kinase activity and 10 showed none. In the majority of cases the mutant ATM protein was unstable, although this was variable. Reduction in ATM kinase activity can result either from the presence of low levels of unstable mutant protein with relatively normal specific kinase activity or from stable mutant protein with deficient ATM kinase activation. Indeed, ATM mutant proteins without kinase activity toward downstream targets were still able to autophosphorylate on serine 1981, although in a much less efficient manner, suggesting that this was not sufficient for ATM activation. In terms of function, green fluorescent protein (GFP)-tagged kinase inactive ATM proteins could form ionizing radiation (IR)-induced foci (IRIF), at least temporarily, which colocalized with the DNA double-strand break (DSB) marker gammaH2AX. Consistent with this, both kinase active and inactive mutant ATM proteins were able to interfere with phosphorylation of targets by endogenous ATM. Since the majority of missense mutations occurred C-terminal to aa1966, including all 10 mutations with absence of kinase activity, the implication was that mutations N-terminal to this, with exceptions, are less likely to result in loss of kinase activity and therefore, are less likely to be identified in A-T patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19431188     DOI: 10.1002/humu.21034

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  17 in total

1.  Underexpression and abnormal localization of ATM products in ataxia telangiectasia patients bearing ATM missense mutations.

Authors:  Virginie Jacquemin; Guillaume Rieunier; Sandrine Jacob; Dorine Bellanger; Catherine Dubois d'Enghien; Anthony Laugé; Dominique Stoppa-Lyonnet; Marc-Henri Stern
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

2.  Characterisation of ATM mutations in Slavic Ataxia telangiectasia patients.

Authors:  Jana Soukupova; Petr Pohlreich; Eva Seemanova
Journal:  Neuromolecular Med       Date:  2011-08-11       Impact factor: 3.843

3.  Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.

Authors:  Kenneth L Pitter; Dana L Casey; Yue C Lu; Margaret Hannum; Zhigang Zhang; Xinmao Song; Isabella Pecorari; Biko McMillan; Jennifer Ma; Robert M Samstein; Isaac X Pei; Atif J Khan; Lior Z Braunstein; Luc G T Morris; Christopher A Barker; Andreas Rimner; Kaled M Alektiar; Paul B Romesser; Christopher H Crane; Joachim Yahalom; Michael J Zelefsky; Howard I Scher; Jonine L Bernstein; Diana L Mandelker; Britta Weigelt; Jorge S Reis-Filho; Nancy Y Lee; Simon N Powell; Timothy A Chan; Nadeem Riaz; Jeremy Setton
Journal:  J Natl Cancer Inst       Date:  2021-03-01       Impact factor: 13.506

4.  Inhibition of ATM kinase activity does not phenocopy ATM protein disruption: implications for the clinical utility of ATM kinase inhibitors.

Authors:  Serah Choi; Armin M Gamper; Jason S White; Christopher J Bakkenist
Journal:  Cell Cycle       Date:  2010-10-27       Impact factor: 4.534

5.  Autosomal recessive adult onset ataxia.

Authors:  Nataša Dragašević-Mišković; Iva Stanković; Andona Milovanović; Vladimir S Kostić
Journal:  J Neurol       Date:  2021-09-09       Impact factor: 4.849

6.  Variant ataxia telangiectasia: clinical and molecular findings and evaluation of radiosensitive phenotypes in a patient and relatives.

Authors:  Kathleen Claes; Julie Depuydt; A Malcolm R Taylor; James I Last; Annelot Baert; Peter Schietecatte; Veerle Vandersickel; Bruce Poppe; Kim De Leeneer; Marc D'Hooghe; Anne Vral
Journal:  Neuromolecular Med       Date:  2013-04-30       Impact factor: 3.843

7.  Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours.

Authors:  A Reiman; V Srinivasan; G Barone; J I Last; L L Wootton; E G Davies; M M Verhagen; M A Willemsen; C M Weemaes; P J Byrd; L Izatt; D F Easton; D J Thompson; A M Taylor
Journal:  Br J Cancer       Date:  2011-07-26       Impact factor: 7.640

8.  Loss of ATM kinase activity leads to embryonic lethality in mice.

Authors:  Jeremy A Daniel; Manuela Pellegrini; Baeck-Seung Lee; Zhi Guo; Darius Filsuf; Natalya V Belkina; Zhongsheng You; Tanya T Paull; Barry P Sleckman; Lionel Feigenbaum; André Nussenzweig
Journal:  J Cell Biol       Date:  2012-08-06       Impact factor: 10.539

9.  The role of ATM in the deficiency in nonhomologous end-joining near telomeres in a human cancer cell line.

Authors:  Keiko Muraki; Limei Han; Douglas Miller; John P Murnane
Journal:  PLoS Genet       Date:  2013-03-28       Impact factor: 5.917

10.  Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice.

Authors:  Kenta Yamamoto; Yunyue Wang; Wenxia Jiang; Xiangyu Liu; Richard L Dubois; Chyuan-Sheng Lin; Thomas Ludwig; Christopher J Bakkenist; Shan Zha
Journal:  J Cell Biol       Date:  2012-08-06       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.